BALCHEM CORP - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - May 10, 2012

Attached files
FileFilename
EXCEL - IDEA: XBRL DOCUMENT - BALCHEM CORPFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR6.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR2.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR8.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR5.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR4.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR9.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR3.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR1.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR28.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR31.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR18.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR32.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR40.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR23.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR25.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR20.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR21.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR19.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR39.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR14.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR13.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR36.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR34.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR26.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR37.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR27.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR10.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR16.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR15.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR38.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR41.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR33.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR17.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR24.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR22.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR11.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR29.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR12.htm
EX-31.2 - EXHIBIT 31.2 - BALCHEM CORPex31_2.htm
EX-32.2 - EXHIBIT 32.2 - BALCHEM CORPex32_2.htm
EX-31.1 - EXHIBIT 31.1 - BALCHEM CORPex31_1.htm
EX-32.1 - EXHIBIT 32.1 - BALCHEM CORPex32_1.htm
10-Q - BALCHEM CORPORATION 10-Q 3-31-2012 - BALCHEM CORPform10q.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR7.htm
XML - IDEA: XBRL DOCUMENT - BALCHEM CORPR35.htm
v2.4.0.6
STOCKHOLDERS' EQUITY (Details) (USD $)
 3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Impact of compensation cost on net earnings $ (611,000) $ (648,000)
Weighted Average Exercise Price [Abstract]    
Aggregate intrinsic value for outstanding stock options 65,043,000 57,930,000
Aggregate intrinsic value for outstanding stock options 38,592,000 66,700,000
Aggregate intrinsic value for exercisable stock options 37,218,000 57,530,000
Weighted average remaining contractual term for outstanding stock options (in years) 5.7 6.1
Weighted average remaining contractual term for exercisable stock options (in years) 4.8 5.2
Weighted Average Assumptions [Abstract]    
Unrecognized compensation cost related to non-vested share-based compensation arrangements 7,836 7,947
Weighted-average period for unrecognized compensation 1.4  
Estimated share-based compensation expense 3,900  
Stock splits and repurchase of common stock    
Number of shares authorized to be repurchased (in shares) 3,763,038  
Number of shares acquired under the stock repurchase plan and subsequently reissued (in shares) 2,033,700  
Number of shares acquired under stock repurchase plan (in shares) 23,212  
Treasury stock acquired, average cost (in dollars per share) $ 41.53  
Stock Options [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares available for future awards (in shares) 4,522,724  
Vesting period (in years) 3Y  
Stock Option Activity [Abstract]    
Outstanding at beginning of year (in shares) 2,514,000 2,955,000
Granted (in shares) 220,000 2,000
Exercised (in shares) (66,000) (84,000)
Forfeited (in shares) (2,000) (4,000)
Outstanding at end of year (in shares) 2,666,000 2,869,000
Exercisable at end of year (in shares) 2,091,000 2,148,000
Weighted Average Exercise Price [Abstract]    
Outstanding at beginning of year (in dollars per share) $ 14.68 $ 14.21
Granted (in dollars per share) $ 29.06 $ 34.10
Exercised (in dollars per share) $ 7.59 $ 11.74
Forfeited (in shares) $ 28.99 $ 24.01
Outstanding at end of year (in dollars per share) $ 16.03 $ 14.28
Exercisable, end of period (in dollars per share) $ 12.50 $ 10.77
Weighted-average fair value of options granted (in dollars per share) $ 9.73 $ 11.00
Total intrinsic value of stock options exercised 2,180,000 1,942,000
Weighted Average Assumptions [Abstract]    
Dividend yields (in hundredths) 0.50% 0.60%
Expected volatility (in hundredths) 41.00% 39.00%
Risk-free interest rates (in hundredths) 0.80% 1.70%
Expected term (in years) 4.6 4.4
Restricted Stock [Member]
    
Non-vested restricted stock [Roll Foward]    
Non-vested balance as of beginning of period (in shares) 354,000 363,000
Granted (in shares) 44,000   
Vested (in shares) (80,000)   
Non-vested balance as of end of period (in shares) 318,000 363,000
Weighted average grant date fair value [Abstract]    
Non-vested balance as of beginning of period (in dollars per share) $ 18.77 $ 17.66
Granted (in dollars per share) $ 29.06   
Vested (in dollars per share) $ 13.72   
Non-vested balance as of end of period (in dollars per share) $ 21.48 $ 17.66
Restricted Stock [Member] | Employee [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting period (in years) 4Y  
Restricted Stock [Member] | Non-employee Director [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting period, minimum (in years) 4Y  
Vesting period, maximum (in years) 7Y  
ISO Plan [Member] | Stock Options [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expiration period of options granted (in years) 10Y  
Non-Qualified Plan [Member] | Stock Options [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expiration period of options granted (in years) 10Y  
Cost of Sales [Member]
    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Impact of compensation cost on earnings component 144,000 145,000
Operating Expenses [Member]
    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Impact of compensation cost on earnings component $ 830,000 $ 884,000

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by BALCHEM CORP and has no official or unofficial affiliation with BALCHEM CORP


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.